MilliporeSigma has entered into a set of agreements with Evotec to expedite screening of customised CRISPR and shRNA libraries for a rapid and efficient exploration of disease pathways.

Under the agreements, Evotec will provide screening services for MilliporeSigma's collection of genetic reagents such as CRISPR and shRNA libraries.

MilliporeSigma applied solutions strategic marketing and innovation head said: "Drug discovery starts with the identification of new targets, a process that can be time and labor intensive.

"Our collaboration with Evotec accelerates the discovery workflow, enabling customers to more rapidly and efficiently explore disease pathways and find new targets."

The collaboration is expected to enable selection of customised set of CRISPR and shRNA libraries, and use Evotec's capabilities in phenotypic screening within primary and induced pluripotent stem cells and in vivo disease models.

"Deploying MilliporeSigma's assay-ready reagents on our cellular screening platforms and in-vivo models creates powerful drug discovery capabilities and more value to our customers through such a comprehensive solution."

The custom-engineered cell lines developed by MilliporeSigma's Cell Design Studio will further facilitate the target identification workflow as it will be used by Evotec to customise screening assays.

Evotec chief operating officer Dr Mario Polywka said: "This agreement with MilliporeSigma further strengthens our offering in the area of target identification and validation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Deploying MilliporeSigma's assay-ready reagents on our cellular screening platforms and in-vivo models creates powerful drug discovery capabilities and more value to our customers through such a comprehensive solution."


Image: A hand holding a pen infront of a strand of DNA. Photo: courtesy of MilliporeSigma.